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The ULTIMATE Step Toward Definitive Evidence?*Carlo di Mario, MD, PHD,a Konstantinos C. Koskinas, MD, MSC,b Lorenz Räber, MD, PHDbSEE PAGE 3126I t has been more than 40 years since the firstballoon angioplasty and 30 years since the firststent implantation. Technical advances in de-
vices and procedural techniques, along with advances
in adjunctive antiplatelet treatments and an overall
better understanding of the physiology of ischemic
heart disease, have led to substantial improvement
in outcomes. Consequently, percutaneous coronary
interventions (PCI) have been widely adopted. The
journey of intracoronary imaging is strikingly
different. Intravascular ultrasound (IVUS), an imag-
ing modality that can visualize native as well as
stented coronary vessels much better than angiog-
raphy, was introduced almost 30 years ago. Despite
this, IVUS is far from having become a routine tool
in everyday clinical practice with a penetration in
single-digit or low-teens figures in Europe and the
United States. Some cardiologists blame an insuffi-
ciently compelling evidence of clinical benefit, but
this does not explain why IVUS has already made a
real breakthrough in Japan and Korea (1).
Historically, IVUS gained widespread attention
soon after its introduction when Colombo et al. (2)
and others showed that an angiographically good
stent result frequently conceals poorly expanded
struts with nasty edge dissections that inevitably in-
crease the risk of acute complications. Initial effortsISSN 0735-1097/$36.00
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show improved outcomes failed when IVUS was used
to optimize bare-metal stent implantation (3,4). In
the drug-eluting stent (DES) era, multiple observa-
tional and randomized clinical trials (RCTs) (5,6)
showed promising results, overall pointing to the
potential of IVUS guidance to further improve
PCI outcomes (7) despite the low thrombosis and
restenosis rates of current newer-generation
DES (approximately 0.5% to 1% and 4% to 6%,
respectively).In this issue of the Journal, Zhang et al. (8) report
the results of the ULTIMATE (Intravascular Ultra-
sound Guided Drug Eluting Stents Implantation in
“All-Comers” Coronary Lesions) trial, a randomized
study conducted in 8 Chinese centers including 1,448
all-comer patients and comparing IVUS versus
angiographic guidance for DES implantation. At
12 months, a 47% reduction in the primary outcome of
target vessel failure (a composite of cardiac death,
myocardial infarction, or target vessel revasculariza-
tion) was observed (from 5.4% using IVUS to 2.9%
with angiography alone; p ¼ 0.019). Although all
components of the composite endpoint were numer-
ically lower in the IVUS-guided group, the reduction
in target vessel failure was driven mainly by a
reduction in target vessel revascularization (2.9% vs.
1.5%; p ¼ 0.07). The Society for Cardiovascular Angi-
ography and Interventions criteria were adopted for
periprocedural myocardial infarction, and it is some-
what surprising that an IVUS strategy potentially
leading to larger and longer stents more often post-
dilated at higher pressure reduced creatine kinase-
MB release in the absence of differences with
respect to acute stent thrombosis.https://doi.org/10.1016/j.jacc.2018.10.029
J A C C V O L . 7 2 , N O . 2 4 , 2 0 1 8 di Mario et al.
D E C E M B E R 1 8 , 2 0 1 8 : 3 1 3 8 – 4 1 Clinical Benefit of IVUS Guidance for Coronary Stenting
3139Against a background of previous RCTs showing a
clinical benefit of IVUS guidance in selected lesion
subsets (i.e., long [5] or chronically occluded [6] le-
sions), the authors categorize the ULTIMATE trial as
an all-comers study. Still, they enrolled mainly a
complex stable coronary artery disease (CAD) popu-
lation with 30% of patients with either a left main
coronary artery lesion, chronic total occlusion, or
bifurcation treated with 2 stents. Notably, the average
lesion (35  22 mm) and stent length (66  46 mm) in
the ULTIMATE trial and in the previous IVUS-XPL
(Impact of IntraVascular UltraSound Guidance on
Outcomes of Xience Prime Stents in Long Lesions)
trial (5), focused on >28-mm long lesions were almost
identical. Still, benefit was not limited to the most
complex lesions. The absolute reduction of events
with IVUS was greater in the American College of
Cardiology/American Heart Association class A/B1
than in class B2/C lesion types (2.8% vs. 2.3%,
respectively).
The benefit of IVUS guidance was also greater
among patients who met all 3 criteria for optimal
IVUS-guided PCI (53% of patients)—a finding sup-
porting the relevance of these criteria. The criteria
proposed in the ULTIMATE trial include stent
expansion, plaque burden at the stent edge, and
absence of large edge dissections. These criteria were
met in only 53%. Stent expansion was defined in a
very conservative manner (i.e., a minimal lumen area
>90% of the distal reference lumen [RLA]), and
accordingly, it was achieved in most lesions. This is at
variance to results in trials using more aggressive
criteria (e.g., minimal stent area > distal RLA, mini-
mal stent area >80% or even >90% of the average
RLA) with poor success in meeting these cutoffs (40%
to 90%) (9). The second criterion, a <50% plaque
burden in the reference segment, was the most
common cause of failure of the IVUS strategy.
Adequate lesion coverage requires careful planning
based on a pre-procedural IVUS pullback, ideally with
the use of coregistration between IVUS and angiog-
raphy. How often pre-stenting IVUS was applied and
whether coregistration was used is not specified in
the paper, but the quite modest difference in stent
length between groups (w3 mm) suggests an infre-
quent adoption of such a strategy. Nevertheless,
every operator performing imaging-guided complex
PCI must acknowledge that avoidance of residual
plaque burden >50% may not be readily possible
unless a full-metal jacket strategy is pursued. In such
situations, it appears important to at least avoid re-
sidual disease burden in the presence of lipid-rich
plaques because they seem to be essential triggers
of edge restenosis (9).How much do the results of the ULTIMATE trial
add to the existing evidence, and what are the po-
tential clinical implications? A European Association
of Percutaneous Cardiovascular Interventions
consensus document appraising the clinical role of
intracoronary imaging recently reported a pooled
analysis of available RCTs comparing IVUS-guided
versus angiography-guided DES implantation (9).
Following up on that report, we performed an upda-
ted meta-analysis that incorporates the ULTIMATE
trial data. The meta-analysis includes 9 RCTs and
4,724 patients and confirms the superiority of IVUS
guidance in the reduction in major adverse cardiac
events (relative risk [RR]: 0.62; 95% confidence in-
terval [CI]: 0.51 to 0.77) and target lesion revascular-
ization (RR: 0.58; 95% CI: 0.43 to 0.78) (Figure 1). Two
aspects are novel. First, compared with the pre-
ULTIMATE data, there is now for the first time a sta-
tistically significant, robust 49% relative risk reduc-
tion in cardiac mortality (RR: 0.51; 95% CI: 0.27 to
0.96) with all individual point estimates going in the
same direction. Second, and of relevance for future
recommendations, 2 large RCTs with >1,000 patients
each consistently showed a reduction in major
adverse cardiac events with IVUS guidance (5,8).
The Class IIb recommendation for the use of IVUS
(or optical coherence tomography) to guide PCI in
earlier clinical practice guidelines were upgraded to
Class IIa indication in the most recent European
guidelines on myocardial revascularization (10). The
question arises: after a positive, large, “all-comers”
trial, are we now ready to recommend routine IVUS
guidance in all patients, or should this still be
restricted to selected patient and lesion subsets—and
if so, to which groups? A closer look at the charac-
teristics of patients included in the ULTIMATE trial is
essential to address this critical question, and as
mentioned earlier in the text, the included patients
mainly belong to a complex stable CAD category
rather than to an all-comers population by current
standards. The impact of the ULTIMATE trial results
on future recommendations remains to be deter-
mined, also in anticipation of 2 largescale optical
coherence tomography guidance studies currently
underway.
Are there downsides to a broader use of IVUS in
clinical practice against the obvious benefits using
IVUS? High cost, lack of availability, and prolongation
of the procedure are often cited as reasons (or ex-
cuses) to justify the reluctance to move beyond
angiography-oriented routine. The cost of the IVUS
approach was not assessed in this paper, but previous
analyses already showed that an IVUS-guided strat-
egy is cost-effective. The safety of IVUS guidance did
FIGURE 1 Forrest Plot Comparing IVUS-Guided With Angiography-Guided PCI With DES
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The Forrest plot summarizes the effects on cardiovascular outcomes of IVUS-guided as compared with angiography-guided PCI with DES. AIR-CTO ¼ Study Comparing
Angiography- vs. IVUS-Guided Stent Implantation for Chronic Total Occlusion in Coronary Artery trial; AVIO ¼ Angiography Vs. IVUS Optimization trial; CI ¼ confidence
interval; CV ¼ cardiovascular; DES ¼ drug-eluting stents; IVUS ¼ intravascular ultrasound; IVUS-XPL ¼ Impact of IntraVascular UltraSound Guidance on Outcomes of
Xience Prime Stents in Long Lesions trial; MACE ¼ major adverse cardiac events; PCI ¼ percutaneous coronary intervention; RR ¼ relative risk; TLR ¼ target lesion
revascularization; ULTIMATE ¼ Intravascular Ultrasound Guided Drug Eluting Stents Implantation in “All-Comers” Coronary Lesions trial.
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3141not emerge as a concern in previous studies (7), as
well as in the ULTIMATE trial. The increase in pro-
cedural time of 15 min is acceptable in view of the
CAD complexity. The 17-ml increase in contrast use in
the IVUS group (8) is probably connected to the study
protocol, and in clinical practice, IVUS even allows
minimal-contrast procedures. The ease of use of im-
aging represents an ongoing issue, which may be
resolved in the future by better software.
The ULTIMATE trial is an important addition to the
body of evidence investigating the role of IVUS in
optimizing PCI. The investigators should be com-
mended for accepting—and eventually overcoming—
the challenge to prove superiority of IVUS in patientswith mainly (but not exclusively) complex CAD.
Collectively, and particularly in view of the totality of
RCT evidence, there is no question that the use of
IVUS guidance to optimize PCI does improve patient
prognosis. Against this background, there is no sci-
entific justification for the observed inertia in inte-
grating an imaging-guided strategy more broadly in
clinical practice.
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